Arun Kanakkanthara
5PUBLICATIONS
16CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Jan 14, 2026
Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancer.Julie R Duffield, Xiaonan Hou, Benjamin W Wilson
|Nov 23, 2021
Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.Arun Kanakkanthara, Xiaonan Hou, Thomas L Ekstrom
|Jul 05, 2021
VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases.Thomas L Ekstrom, Nicholas M Pathoulas, Amelia M Huehls
|Oct 18, 2019
BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.Arun Kanakkanthara, Kiran Kurmi, Thomas L Ekstrom
|Oct 13, 2019
ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer.Arun Kanakkanthara, Catherine J Huntoon, Xiaonan Hou
Pageof 1
Frequent Collaborators
4 joint publications
Ann L Oberg
4 joint publications
Scott H Kaufmann
3 joint publications
Thomas L Ekstrom
2 joint publications
Cristina Correia
1 joint publications
Nicholas M Pathoulas
1 joint publications
Valentina Zanfagnin
1 joint publications
Aaron S Mansfield
1 joint publications
Julie R Duffield
1 joint publications
Xiaonan Hou
1 joint publications
Anjali Prasad
